Completed PHASE4 INTERVENTIONAL NCT00311870

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

Sponsor: Bayer

Updated 6 times since 2017 Last updated: Apr 4, 2006 Started: Mar 31, 1993 Completion: Apr 30, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00311870, this PHASE4 trial focuses on Diabetic Nephropathy and remains completed. Sponsored by Bayer, it has been updated 6 times since 1993, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2019 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2019 [monthly]

Completed PHASE4

First recorded

Mar 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Steno Diabetes Center Copenhagen

Data source: Steno Diabetes Center Copenhagen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gentofte Municipality, Denmark